Back to News
May 13, 2026 12:10 PM

Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform

Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. (NASDAQ:AZN) to develop specialized biopharma AI agents using its K Pro platform, expanding the companies' existing collaboration in drug discovery and development.

The agreement will allow Owkin to build end-to-end AI agents designed to operate within AstraZeneca's internal infrastructure and decision-making workflows.

The companies said the tools are intended to support competitive intelligence and provide faster access to data-driven insights while reducing reliance on manual analysis.

Read Also:

AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements

K Pro To Support Biopharma Decision Making

Owkin described K Pro as an "AI Scientist" platform built for pharmaceutical research and strategic decision-making.

The platform combines multimodal data with agentic AI tools aimed at helping researchers ...